时隔5个月，新氧与童颜针上游企业的矛盾再次激化。 11月22日，童颜针厂商普丽妍宣布非官方合作医疗机构79家，其中包括北京新氧科技有限公司（下称"新氧"）旗下46家新氧青春诊所。普丽妍称其为黑名单 医美机构、非合作医生。新氧随即发布声明反击，称一切均为合法合规。 多家被普丽妍列入"黑名单"的医美机构负责人告诉经济观察报，普丽妍的举动是为维护其产品的价格体系，因为在这些机构出售的普丽妍童颜针价格普遍低 于它的指导价格。 新氧的定价最典型：在它的诊所里，含有普丽妍童颜针的项目卖5999元/支，比普丽妍的指导价格低了6成。这也正是新氧从平台转到线下机构时提出的核心 经营模式——通过整合供应链、压缩上游高毛利等方式，"击穿底价"。 新氧用低价搅动医美圈也曾遭到锦波生物、长春圣博玛生物材料有限公司（下称"圣博玛"）的质疑。这次双方矛盾的升级是医美产业链上下游利益再分配的 新挑战。 争端缘起 普丽妍对包括新氧在内的医美机构提出两点质疑：一是不存在任何正式合作关系，均非官方授权，普丽妍不承担正品保证；二是未对其医护人员进行专业注 射培训。 普丽妍是一家医美上游企业，专注于医用高分子材料和生物组织工程领域，主要产品为普丽妍· ...

Core Viewpoint - The ongoing conflict between upstream manufacturers and downstream medical beauty institutions highlights issues of product authorization and market competition in the rapidly expanding medical beauty industry in China [2][5][12]. Group 1: Conflict Overview - Puli Yan accused several medical institutions, including Anhui Hefei Hanmei Plastic Surgery Hospital and Xinyang Youth Clinic, of being "unauthorized cooperation institutions," warning of potential health risks for consumers due to unverified product sourcing [1][2]. - Xinyang responded by asserting that all Puli Yan products used are sourced from legally qualified suppliers and emphasized compliance with ISO 37301 management standards [1][2]. Group 2: Market Dynamics - The medical beauty market, particularly the "童颜针" (youthful needle) segment, has seen rapid growth, with market size increasing from over 1 billion yuan in 2021 to an estimated 30 billion yuan last year, projected to reach 100 billion yuan in five years [5][6]. - Xinyang's introduction of lower-priced products, such as the "奇迹童颜" series, has disrupted the pricing structure established by upstream manufacturers, leading to tensions and demands for product removal from the market [5][6]. Group 3: Compliance and Regulation - Concerns have been raised regarding Xinyang's compliance with regulations, as some manufacturers claim that Xinyang has used products without proper authorization, potentially jeopardizing consumer safety [8][9]. - Legal experts emphasize that medical institutions must procure products from authorized sources to ensure traceability and compliance with regulations, highlighting the risks associated with unauthorized procurement [9][12]. Group 4: Industry Challenges - The medical beauty industry faces significant challenges, including the prevalence of unauthorized sales and counterfeit products, which threaten consumer safety and complicate regulatory enforcement [12][13]. - The need for a collaborative approach among manufacturers, medical institutions, and regulatory bodies is critical to establish a sustainable and compliant industry ecosystem [14].

"新氧尊重上游合作伙伴的合理商业安排，但坚决反对任何以'安全'为名、通过传播不实或误导性信息来损害医疗机构商誉、制 造消费者恐慌、干预正常市场竞争的行为。"新氧青春诊所进一步表示，这既伤害了消费者的信任，也破坏了行业应有的专业与 秩序。 在业内看来，这场围绕产品授权、渠道合规的交锋，背后是上游厂商与终端医美机构对产品定价权的博弈。而在我国持续扩容 的医美市场中，未经官方授权却售卖相关产品的现象并不鲜见，这一行业痛点也愈发凸显我国医美产业从"野蛮生长"向"规范发 展"转型的必然趋势。 医美行业上游厂商与终端机构之间的"拉锯战"正浮出水面。 日前，普丽妍通过官微发布声明，直指安徽合肥韩美整形外科医院、新氧青春诊所等医疗机构为"非官方授权合作机构"，称其 未通过正规渠道采购产品，公司不保障产品真伪，且未对相关医护人员开展过产品专业培训，警示存在消费者健康安全风险。 面对普丽妍的公开"指控"，新氧青春诊所也迅速回应。一方面，其明确表示所用普丽妍产品均由具备医疗器械经营资质的企业 依法供货，可通过国家药监部门 UDI（医疗器械唯一标识）进行真伪查询和全流程追溯；同时强调新氧全国门店均为依法批准 的医疗机构，相关医生执业 ...

Core Viewpoint - The ongoing conflict between upstream manufacturers and downstream medical beauty institutions highlights the challenges in product authorization and market pricing within the medical aesthetics industry, indicating a shift from "wild growth" to "regulated development" in China’s medical beauty market [4][5]. Group 1: Industry Dynamics - The medical beauty industry is experiencing a tug-of-war over product pricing and authorization, with companies like Purity and New Oxygen at the forefront of this conflict [4][5]. - New Oxygen's low pricing strategies for products like "Miracle Youth 3.0" have disrupted traditional pricing structures, leading to tensions with upstream manufacturers [8][9]. - The market for youth-enhancing products, such as the "童颜针" (youth needle), has seen rapid growth, with estimates suggesting it will reach a scale of 100 billion in five years, up from over 30 billion last year [7]. Group 2: Compliance and Regulation - There are significant compliance concerns regarding the sourcing of medical products, with allegations that New Oxygen has used products without proper authorization, raising questions about product safety and traceability [11][12]. - Legal experts emphasize the importance of purchasing medical devices from authorized sources to ensure compliance with regulations, highlighting the potential penalties for non-compliance [12]. - The medical beauty industry faces challenges with counterfeit products and unauthorized sales, necessitating stronger regulatory measures and consumer awareness [15][16]. Group 3: Consumer Safety and Market Integrity - The prevalence of unauthorized medical beauty institutions and counterfeit products poses a significant risk to consumer safety, with only 35% of products in circulation being genuine [9][15]. - Industry leaders argue that lowering prices for legitimate medical beauty services is essential to combat the prevalence of "black medical beauty" practices, which thrive on high prices in the legitimate market [9][10]. - There is a call for a collaborative approach among manufacturers, medical institutions, and regulatory bodies to ensure consumer rights and product quality are prioritized in the evolving medical beauty landscape [17].

Market Overview - On November 28, A-shares opened slightly lower, with the Shanghai Composite Index down 0.11% at 3870.94 points, the Shenzhen Component Index down 0.04% at 12869.66 points, and the ChiNext Index down 0.04% at 3029.98 points [1] - The market saw gains in sectors such as precious metals, while small metals and short drama games faced declines [1] - Notable stocks included Guosheng Technology, which opened up 1.23%, and Furi Shares, which opened down 4.00% [1] Company News - Dongxin Co., Ltd. signed a strategic cooperation framework agreement with a leading domestic cloud computing service provider to collaborate on various technology solutions [2] - Tianpu Co. applied for a stock suspension starting November 28, 2025, to protect investor interests [2] - Fule New Materials has successfully transitioned from a material supplier to a smart sensing solution provider with its "electronic skin" product [2] - Wantong Development is progressing with its strategic transformation involving Shudu Technology, which is currently in a loss-making state [2] - Moer Thread's recent share issuance saw 16.77 million shares subscribed, raising 1.917 billion yuan [2] Industry Insights - The AI glasses market is seeing growth with Alibaba's launch of the Quark AI glasses, which integrate various services from its ecosystem [5] - The AI unicorn "Moon's Dark Side" is nearing the end of its latest funding round, with a valuation expected to reach approximately $4 billion [6] - Chongqing's government has introduced policies to support the low-altitude economy, offering subsidies up to 20 million yuan [7] - The lithium battery supply chain is strengthening with long-term supply agreements totaling 159.5 thousand tons [8] - The consumer electronics sector is expanding, with a total of 230 million product varieties available in China [9] - The film industry is experiencing success with "Zootopia 2" achieving a record box office on its opening day [10] - The ice and snow economy is gaining traction, with increased flight bookings to popular destinations [11] Institutional Perspectives - Huatai Securities predicts rapid growth for satellite industry-related stocks due to advancements in reusable rockets and reduced launch costs [12] - Zhongyuan Securities highlights the solar industry entering a capacity clearing cycle, suggesting improved performance for existing companies [13] - Tianfeng Securities notes the rapid development of China's medical beauty market, with significant growth potential in various segments [14]

Group 1: Robotics Industry - The robotics technology route is continuously iterating, with new entrants in the industry, leading to increased market focus on product performance and customer sampling progress [1] - The successful finalization of Tesla's Optimus is expected to drive marginal convergence in hardware technology routes, benefiting companies that can deeply integrate and secure direct orders [1] - Three categories of investment targets are recommended: high-probability Tesla supply chain participants, incremental segments aligned with technological upgrades, and undervalued high-performance companies with expected growth [1] Group 2: Satellite Industry - The satellite industry is poised for rapid growth as China's reusable rocket technology matures, enhancing launch capacity and reducing costs [2] - This development is expected to enable satellite companies to increase production capacity and accelerate network deployment, shortening the production and launch cycle for satellites [2] Group 3: Medical Aesthetics Industry - The medical aesthetics market in China is developing rapidly, with light medical aesthetics gaining popularity among consumers [3] - There remains significant potential for growth in the medical aesthetics market when compared to mature markets, particularly in injection, photonic equipment, fat reduction/shaping, and medical aesthetic services [3] - A strong regulatory environment is accelerating industry consolidation, guiding the medical aesthetics market towards healthier and more orderly development [3]

Market Overview - The market experienced a mixed performance yesterday, with the Shanghai Composite Index rising by 0.29%, while the Shenzhen Component Index and the ChiNext Index fell by 0.25% and 0.44% respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.71 trillion yuan, a decrease of 736 billion yuan compared to the previous trading day [1] - Sectors such as organic silicon, batteries, and consumer electronics saw significant gains, while sectors like Hainan, film and television, and AI applications faced declines [1] Satellite Industry - Huatai Securities predicts a rapid growth phase for satellite industry chain-related stocks, driven by the maturation of reusable rockets, increased launch capacity, and decreasing launch costs [2] - These factors are expected to enhance satellite companies' production capacity and accelerate network deployment, shortening the production and launch cycle of satellites [2] Photovoltaic Industry - Zhongyuan Securities indicates that the photovoltaic industry will enter a sustained capacity clearing cycle by 2026, influenced by "anti-involution" measures, mergers and acquisitions, and higher industry entry barriers [3] - The competitive landscape and ecosystem of the photovoltaic industry are expected to improve, leading to a gradual enhancement in the performance of existing photovoltaic companies [3] - Public funds currently have low allocations in the photovoltaic sector, but undervaluation and improved supply-demand dynamics may attract more capital [3] - Recommendations include focusing on leading companies in sub-sectors such as energy storage inverters, polysilicon materials, photovoltaic glass, and integrated component manufacturers [3] Medical Aesthetics Market - Tianfeng Securities highlights the rapid development of China's medical aesthetics market, with light medical aesthetics gaining popularity among consumers [4] - There remains significant room for growth in China's medical aesthetics market compared to mature markets, particularly in four sub-sectors: injectables, optical devices, body sculpting, and medical aesthetic services [4] - A strong regulatory environment is accelerating the industry's survival of the fittest, guiding the medical aesthetics market towards healthier and more orderly development [4]

Core Viewpoint - The Chinese medical beauty market is rapidly developing, with light medical beauty gaining increasing popularity among consumers [1] Market Potential - The penetration rate of the medical beauty market in China has significant room for improvement compared to mature markets [1] Market Segmentation - The four major segments of the medical beauty industry—injectables, photonic devices, fat reduction/body shaping, and medical beauty services—show considerable growth potential [1] Regulatory Environment - A strong regulatory environment is accelerating the survival of the fittest within the industry, guiding the medical beauty market towards a healthier and more orderly development trajectory [1]

Core Insights - The Chinese medical beauty market is experiencing rapid growth, with light medical beauty increasingly favored by consumers [1] - There is significant room for improvement in China's medical beauty market compared to mature markets, particularly in terms of penetration rates [1] - The four major segments of the medical beauty industry—injectables, photonic devices, fat reduction/body shaping, and medical beauty services—show considerable growth potential [1] - A strong regulatory environment is accelerating the process of industry consolidation, guiding the medical beauty market towards a healthier and more orderly development trajectory [1]

Group 1 - The company *ST Jinbi (SZ 002762) announced that its 23rd meeting of the fifth board of directors was held on November 27, 2025, to discuss the proposal for the board's re-election [1] - For the first half of 2025, the revenue composition of *ST Jinbi was 77.64% from the maternal and infant consumer goods sector, 21.03% from the medical beauty sector, and 1.33% from other sources [1] - As of the report date, *ST Jinbi's market capitalization was 2.7 billion yuan [1]